Hepion Pharmaceuticals votes reverse stock split of 1-for-20 to 1-for-50

Hepion Pharmaceuticals majority stockholders executed written consent on Aug. 27, 2026, clearing a package of charter and equity-plan changes.

• The board gained authority to implement a reverse stock split within a 1-for-20 to 1-for-50 range, at its discretion.
• A charter amendment authorized a jump in common shares to 750,000,000 from 120,000,000, expanding capacity for future issuance.
• The 2023 Omnibus Equity Incentive Plan share pool increased to 18,000,000 from 8,000,000.
• The actions take effect at least 20 days post-mailing.